

浏览全部资源
扫码关注微信
1.深圳市人民医院/暨南大学第二临床医学院/南方科技大学第一附属医院药学部,广东 深圳 518020
2.广州医科大学附属第三医院药学部/广东省产科重大疾病重点实验室,广州 510150
Received:24 October 2023,
Revised:2024-03-23,
Accepted:25 March 2024,
Published:15 May 2024
移动端阅览
周佳,谭湘萍,李洁娜,等.1例头孢他啶阿维巴坦致四肢阵发性痉挛的药学监护[J].中国药房,2024,35(09):1145-1150.
ZHOU Jia,TAN Xiangping,LI Jiena,et al.Pharmaceutical care for a patient with paroxysmal spasms of extremities caused by ceftazidime-avibactam[J].ZHONGGUO YAOFANG,2024,35(09):1145-1150.
周佳,谭湘萍,李洁娜,等.1例头孢他啶阿维巴坦致四肢阵发性痉挛的药学监护[J].中国药房,2024,35(09):1145-1150. DOI: 10.6039/j.issn.1001-0408.2024.09.21.
ZHOU Jia,TAN Xiangping,LI Jiena,et al.Pharmaceutical care for a patient with paroxysmal spasms of extremities caused by ceftazidime-avibactam[J].ZHONGGUO YAOFANG,2024,35(09):1145-1150. DOI: 10.6039/j.issn.1001-0408.2024.09.21.
目的
2
探讨临床药师在鉴别药物致阵发性痉挛中的作用,为合理用药提供参考。
方法
2
回顾性分析临床药师对1例使用头孢他啶阿维巴坦(CZA-AVI)导致四肢阵发性痉挛患者的药学监护过程。临床药师鉴别、分析并总结了抗菌药物导致神经系统毒性的临床表现、危险因素及处理方法等,结合患者临床症状和检验结果等情况,建议暂先停用多黏菌素B和孟鲁司特钠,并将CZA-AVI剂量减半。医师未采纳CZA-AVI剂量减半的建议,后患者神经系统毒性仍未好转,临床药师再次建议停用CZA-AVI,医师予以采纳。
结果
2
临床药师通过分析病情,逐一排查导致四肢阵发性痉挛的相关药物,最终确定CZA-AVI可能是导致该患者发生四肢阵发性痉挛的药物;停用该药后患者症状好转,转入社区医院康复治疗。
结论
2
在使用CZA-AVI时,需根据肾功能调整剂量,并警惕其所致的神经系统毒性,尤其是对于高龄、肾功能不全、合并使用多种具有肾毒性及神经系统毒性药物的患者。
OBJECTIVE
2
To explore the role of clinical pharmacists in identifying paroxysmal spasms caused by drugs, and provide reference for rational drug use.
METHODS
2
Retrospective analysis was conducted on pharmaceutical care provided by clinical pharmacists for a patient with ceftazidime-avibactam (CZA-AVI) induced paroxysmal spasms. The clinical pharmacists identified, analyzed and summarized the clinical manifestations, risk factors and treatment methods of the nervous system toxicity caused by antibacterial drugs. According to the patient’s clinical symptoms and test results, the clinical pharmacists recommended temporarily discontinuing the use of polymyxin B and montelukast sodium, and halving the dose of CZA-AVI. The physicians did not adopt the recommendation to halve the dose of CZA-AVI, and when the patient’s neurologic toxicity did not improve, the clinical pharmacists again recommended discontinuing CZA-AVI, which was accepted by the physicians.
RESULTS
2
Clinical pharmacists analyzed the condition and checked related drugs that caused paroxysmal spasms of extremities one by one, and finally determined that CZA-AVI might be the drug that caused paroxysmal spasms of extremities in the patient. After stopping the drug, the patient’s symptoms improved and was transferred to a community hospital for rehabilitation treatment.
CONCLUSIONS
2
The dose of CZA-AVI should be adjusted according to the renal function and the neurotoxicity should be guarded against, especially for patients with advanced age, renal insufficiency, and the combined use of multiple drugs related to nephrotoxicity and neurotoxicity.
赵锦锦 , 张菁 . 头孢他啶-阿维巴坦药品说明书 [J ] . 国外医药(抗生素分册) , 2019 , 40 ( 2 ): 115 - 127 .
ZHAO J J , ZHANG J . Ceftazidime-abamectin drug instructions [J ] . World Notes (Antibiot) , 2019 , 40 ( 2 ): 115 - 127 .
CHENG K R , NEWELL P , CHOW J W , et al . Safety profile of ceftazidime-avibactam:pooled data from the adult phase Ⅱ and phase Ⅲ clinical trial programme [J ] . Drug Saf , 2020 , 43 ( 8 ): 751 - 766 .
邵丹 , 毕铁琳 , 尹航 , 等 . 吸入用复方异丙托溴铵溶液诱发震颤一例 [J ] . 中国医院用药评价与分析 , 2019 , 19 ( 5 ): 639 - 640 .
SHAO D , BI T L , YIN H , et al . One case of tremor induced by compound ipratropium bromide solution for inhalation [J ] . Eval Anal Drug Use Hosp China , 2019 , 19 ( 5 ): 639 - 640 .
李蒙 , 杨晨 , 袁恒杰 . 孟鲁司特钠致严重精神系统紊乱1例 [J ] . 中国药物应用与监测 , 2018 , 15 ( 2 ): 121 - 123 .
LI M , YANG C , YUAN H J . One case of mental disorders induced by montelukast sodium [J ] . Chin J Drug Appl Monit , 2018 , 15 ( 2 ): 121 - 123 .
JUSTO J A , BOSSO J A . Adverse reactions associated with systemic polymyxin therapy [J ] . Pharmacotherapy , 2015 , 35 ( 1 ): 28 - 33 .
KARAISKOS I , GALANI I , PAPOUTSAKI V , et al . Carbapenemase producing Klebsiella pneumoniae :implication on future therapeutic strategies [J ] . Expert Rev Anti Infect Ther , 2022 , 20 ( 1 ): 53 - 69 .
AGBABIAKA T B , SAVOVIĆ J , ERNST E . Methods for causality assessment of adverse drug reactions:a syste- matic review [J ] . Drug Saf , 2008 , 31 ( 1 ): 21 - 37 .
刘双信 , 史伟 , 何思敏 , 等 . 头孢他啶致慢性肾衰竭维持性透析患者中枢神经系统损害 [J ] . 中国血液净化 , 2010 , 9 ( 4 ): 186 - 189 .
LIU S X , SHI W , HE S M , et al . Neurotoxicity induced by ceftazidime treatment in chronic renal failure patients on maintenance hemodialysis [J ] . Chin J Blood Purif , 2010 , 9 ( 4 ): 186 - 189 .
JOSEPH J , VIMALA A . Ceftazidime-induced myoclonus and encephalopathy in hemodialysis patient [J ] . Indian J Nephrol , 2015 , 25 ( 1 ): 61 - 62 .
DESHAYES S , COQUEREL A , VERDON R . Neurological adverse effects attributable to β-lactam antibiotics:a literature review [J ] . Drug Saf , 2017 , 40 ( 12 ): 1171 - 1198 .
ONG C Y , QIN Y . Myoclonus from antibiotic therapy (ceftazidime-induced neurotoxicity):a case report and review [J ] . Cureus , 2018 , 10 ( 3 ): e2250 .
GATTI M , RASCHI E , PONTI F D . Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations:a large-scale pharmacovigilance analysis [J ] . Eur J Clin Microbiol Infect Dis , 2021 , 40 ( 6 ): 1169 - 1176 .
GUO X L , GUO M X , LI J Y , et al . Central nervous system adverse events of ceftazidime/avibactam:a retrospective study using Food and Drug Administration adverse event reporting system [J ] . J Clin Pharm Ther , 2022 , 47 ( 12 ): 2369 - 2372 .
郭晓龙 , 见海超 , 张志琪 , 等 . 基于FAERS的头孢他啶/阿维巴坦致神经系统异常的不良反应信号挖掘与分析 [J ] . 中国医院药学杂志 , 2022 , 42 ( 19 ): 2046 - 2050 .
GUO X L , JIAN H C , ZHANG Z Q , et al . Signal mining and analysis of adverse drug reactions associated with nervous system disorders induced by ceftazidime/avibactam based on FAERS database [J ] . Chin J Hosp Pharm , 2022 , 42 ( 19 ): 2046 - 2050 .
PINGUE V , PENATI R , NARDONE A , et al . Ceftazidime/avibactam neurotoxicity in an adult patient with normal renal function [J ] . Clin Microbiol Infect , 2020 : S1198 - S743 X(20)30727-8.
NORRBY S R . Neurotoxicity of carbapenem antibiotics:consequences for their use in bacterial meningitis [J ] . J Antimicrob Chemother , 2000 , 45 ( 1 ): 5 - 7 .
MARTÍNEZ-RODRÍGUEZ J E , BARRIGA F J , SANTAMARIA J , et al . Nonconvulsive status epilepticus associated with cephalosporins in patients with renal fai- lure [J ] . Am J Med , 2001 , 111 ( 2 ): 115 - 119 .
DENIC A , GLASSOCK R J , RULE A D . Structural and functional changes with the aging kidney [J ] . Adv Chronic Kidney Dis , 2016 , 23 ( 1 ): 19 - 28 .
LACROIX C , KHELOUFI F , MONTASTRUC F , et al . Serious central nervous system side effects of cephalosporins:a national analysis of serious reports registered in the French pharmacovigilance database [J ] . J Neurol Sci , 2019 , 398 : 196 - 201 .
COLLINS R D , TVERDEK F P , BRUNO J J , et al . Pro- bable nonconvulsive status epilepticus with the use of high-dose continuous infusion ceftazidime [J ] . J Pharm Pract , 2016 , 29 ( 6 ): 564 - 568 .
HURKACZ M , DOBREK L , WIELA-HOJEŃSKA A . Antibiotics and the nervous system:which face of antibiotic therapy is real,Dr. Jekyll (neurotoxicity) or Mr. Hyde (neuroprotection)? [J ] . Molecules , 2021 , 26 ( 24 ): 7456 .
REZAEI N J , BAZZAZI A M , NASERI ALAVI S A . Neurotoxicity of the antibiotics:a comprehensive study [J ] . Neurol India , 2018 , 66 ( 6 ): 1732 - 1740 .
BANGERT M K , HASBUN R . Neurological and psychia- tric adverse effects of antimicrobials [J ] . CNS Drugs , 2019 , 33 ( 8 ): 727 - 753 .
KERLING D A , CLARKE S C , DELUCA J P , et al . Systematic review and meta-analysis of the effect of loop diuretics on antibiotic pharmacokinetics [J ] . Pharmaceutics , 2023 , 15 ( 5 ): 1411 .
ABDUL-AZIZ M H , ALFFENAAR J C , BASSETTI M , et al . Antimicrobial therapeutic drug monitoring in critically ill adult patients:a position paper [J ] . Intensive Care Med , 2020 , 46 ( 6 ): 1127 - 1153 .
BEUMIER M , CASU G S , HITES M , et al . Elevated β-lactam concentrations associated with neurological deterioration in ICU septic patients [J ] . Minerva Anestesiol , 2015 , 81 ( 5 ): 497 - 506 .
0
Views
27
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
公网安备50010302001817